| | A Phase 3 Randomized, Double-blind Study of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel for the First-line Treatment of Patients with Her2-positive Metastatic Breast Cancer . . . |
Completed |
05 Aug 2020 |
| | A Phase 3 Randomized, Double-Blind, Active-Controlled, Multicenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects with Osteoarthritis of the Hip or . . . |
Completed |
17 Jul 2019 |
| | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and N . . . |
Ongoing |
12 Apr 2021 |
| | A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Sma . . . |
Ongoing |
06 May 2021 |
| | A Phase 3 Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy. . . . |
Ongoing |
07 Oct 2021 |
| | A Phase 3, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjec . . . |
Ongoing |
17 May 2022 |
| | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine an . . . |
Terminated |
03 Jul 2020 |
| | A phase 3, multicenter, four-week, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of flexible doses of oral ziprasidone in children and adolescents with bipolar . . . |
Terminated |
27 Aug 2020 |
| | A Phase 3, Multicenter, Long-Term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip or Shoulder Replacement . . . |
Completed |
17 Jul 2019 |
| | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreate . . . |
Ongoing |
11 Jan 2022 |
| | A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy And Safety Of FG-4592 For The Treatment Of Anemia In Chronic Kidney Disease Patients Not On Dialysis . . . |
Completed |
02 Aug 2019 |
| | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active . . . |
Completed |
12 Aug 2021 |
| | A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan (APL-2) in Patients with Paroxysmal Nocturnal Hemoglubinuria (PNH) . . . |
Completed |
06 May 2022 |
| | A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients . . . |
Ongoing |
31 Dec 2021 |
| | A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan(T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexe . . . |
Ongoing |
30 Nov -0001 |
| | A Phase II, double-blind, controlled trial to assess the Safety and Immunogenicity of different schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 an . . . |
Completed |
13 Apr 2020 |
| | A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lup . . . |
Ongoing |
20 May 2022 |
| | A Phase II/III, Multicenter, Observer- Blinded, Randomized, Non-inferiority and Safety Study of Typhoid Conjugate Vaccine (EuTCV) Compared to Typar- TCV ® in Healthy 6 Months – 45 Years Aged Partic . . . |
Completed |
03 Nov 2021 |
| | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα- Kinoid in Adult Subjects with System . . . |
Terminated |
30 Apr 2021 |
| | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, . . . |
Ongoing |
19 May 2020 |
| | A Phase III double-blind study to assess safety andefficacy of an RSV Maternal unadjuvanted vaccine,in pregnant women and infants born to vaccinatedmothers . . . |
Ongoing |
03 Aug 2021 |
| | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas . . . |
Ongoing |
24 May 2021 |
| | A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-rel . . . |
Completed |
01 Apr 2022 |
| | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squa . . . |
Ongoing |
30 Oct 2020 |
| | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patie . . . |
Completed |
18 May 2020 |